Seletracetam (Ucb 44212), as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy[1][2][3].
Seletracetam decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A[2].Seletracetam decreases synaptic responses in a time-, frequency- and concentration-dependent manner[2].Seletracetam modifies rates of presynaptic release[2].Seletracetam inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro[3].
[1]. Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7.
[2]. Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10.
[3]. Yang X, et al. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22.